On September 24, 2025, UniQure N.V. announced a $175 million non‑dilutive senior secured term loan facility with Hercules Capital, Inc. The facility is designed to strengthen the company’s financial position and provide the liquidity needed for the potential U.S. launch of its Huntington’s disease therapy, AMT‑130, anticipated in 2026.
The loan is structured in three tranches: a $50 million refinancing of the existing debt, a $100 million drawdown tranche that can be accessed at UniQure’s option once regulatory and financial milestones for AMT‑130 are met, and a third tranche of up to $25 million subject to Hercules’ approval. All tranches carry a floating interest rate of the greater of 9.45% or prime + 2.45%, which is currently 9.70%—a significant reduction from the 11.95% rate that would have applied before refinancing. The tranches mature in October 2030, extending the company’s debt horizon.
By securing this non‑dilutive financing, UniQure preserves shareholder equity while lowering its cost of capital. The lower interest rate and extended maturity provide a more favorable debt profile, giving the company additional runway to complete late‑stage development, regulatory submissions, and commercialization activities for AMT‑130. The transaction underscores UniQure’s commitment to advancing its flagship therapy and strengthens its balance sheet for the critical next phase of its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.